BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 26731987)

  • 1. Epidermal Growth Factor Receptor Inconsistency by Immunohistochemistry Method Using Different Monoclonal Antibodies in Colorectal Cancer Patients.
    Fan CC; Wang TY; Kung CM
    Clin Lab; 2015; 61(11):1635-41. PubMed ID: 26731987
    [TBL] [Abstract][Full Text] [Related]  

  • 2. EGFR-immunohistochemistry in colorectal cancer and non-small cell lung cancer: comparison of 3 commercially available EGFR-antibodies.
    Buffet W; Geboes KP; Dehertogh G; Geboes K
    Acta Gastroenterol Belg; 2008; 71(2):213-8. PubMed ID: 18720932
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Correlation of EGFR expression, gene copy number and clinicopathological status in NSCLC.
    Gaber R; Watermann I; Kugler C; Reinmuth N; Huber RM; Schnabel PA; Vollmer E; Reck M; Goldmann T
    Diagn Pathol; 2014 Sep; 9():165. PubMed ID: 25227424
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Protein overexpression and gene amplification of epidermal growth factor receptor in nonsmall cell lung carcinomas: Comparison of four commercially available antibodies by immunohistochemistry and fluorescence in situ hybridization study.
    Lee HJ; Xu X; Choe G; Chung DH; Seo JW; Lee JH; Lee CT; Jheon S; Sung SW; Chung JH
    Lung Cancer; 2010 Jun; 68(3):375-82. PubMed ID: 19712993
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epidermal growth factor receptor (EGFR) status in primary colorectal tumors correlates with EGFR expression in related metastatic sites: biological and clinical implications.
    Italiano A; Saint-Paul MC; Caroli-Bosc FX; François E; Bourgeon A; Benchimol D; Gugenheim J; Michiels JF
    Ann Oncol; 2005 Sep; 16(9):1503-7. PubMed ID: 15980160
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of two antibodies for immunohistochemical evaluation of epidermal growth factor receptor expression in colorectal carcinomas, adenomas, and normal mucosa.
    Bhargava R; Chen B; Klimstra DS; Saltz LB; Hedvat C; Tang LH; Gerald W; Teruya-Feldstein J; Paty PB; Qin J; Shia J
    Cancer; 2006 Apr; 106(8):1857-62. PubMed ID: 16532444
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunohistochemical discrimination of wild-type EGFR from EGFRvIII in fixed tumour specimens using anti-EGFR mAbs ICR9 and ICR10.
    Modjtahedi H; Khelwatty SA; Kirk RS; Seddon AM; Essapen S; Del Vecchio CA; Wong AJ; Eccles S
    Br J Cancer; 2012 Feb; 106(5):883-8. PubMed ID: 22315050
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combined assessment of epidermal [corrected] growth factor receptor dual color in situ hybridization and immunohistochemistry with downstream gene mutations in prediction of response to the anti-EGFR therapy for patients with metastatic colorectal cancer.
    Takahashi N; Yamada Y; Taniguchi H; Honma Y; Iwasa S; Kato K; Hamaguchi T; Shimada Y
    Arch Med Res; 2014 Jul; 45(5):366-74. PubMed ID: 24830936
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression of epidermal growth factor receptor (EGFR) in colorectal cancer: An immunohistochemical study.
    Ben Brahim E; Ayari I; Jouini R; Atafi S; Koubaa W; Elloumi H; Chadli A
    Arab J Gastroenterol; 2018 Sep; 19(3):121-124. PubMed ID: 30243897
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry.
    Chung KY; Shia J; Kemeny NE; Shah M; Schwartz GK; Tse A; Hamilton A; Pan D; Schrag D; Schwartz L; Klimstra DS; Fridman D; Kelsen DP; Saltz LB
    J Clin Oncol; 2005 Mar; 23(9):1803-10. PubMed ID: 15677699
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High-sensitivity epidermal growth factor receptor immunostaining for colorectal carcinomas, compared with EGFR PharmDx™: a study of diagnostic accuracy.
    Shiogama K; Wongsiri T; Mizutani Y; Inada K; Tsutsumi Y
    Int J Clin Exp Pathol; 2013; 6(1):24-30. PubMed ID: 23236539
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In depth evaluation of the prognostic and predictive utility of PTEN immunohistochemistry in colorectal carcinomas: performance of three antibodies with emphasis on intracellular and intratumoral heterogeneity.
    Ágoston EI; Micsik T; Ács B; Fekete K; Hahn O; Baranyai Z; Dede K; Bodoky G; Bursics A; Kulka J; Krenács T; Győrffy B; Harsányi L; Szász AM
    Diagn Pathol; 2016 Jul; 11(1):61. PubMed ID: 27392434
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discordance between EGFR expression and clinicopathologic parameters of colorectal adenocarcinoma in Taiwan.
    Tsai WC; Lin CK; Lee HS; Chen A; Nieh S; Yu CP; Wu CC; Jao SW; Jin JS
    Chin J Physiol; 2012 Oct; 55(5):352-60. PubMed ID: 23282210
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessment of epidermal growth factor receptor (EGFR) expression in primary colorectal carcinomas and their related metastases on tissue sections and tissue microarray.
    Bibeau F; Boissière-Michot F; Sabourin JC; Gourgou-Bourgade S; Radal M; Penault-Llorca F; Rochaix P; Arnould L; Bralet MP; Azria D; Ychou M
    Virchows Arch; 2006 Sep; 449(3):281-7. PubMed ID: 16865406
    [TBL] [Abstract][Full Text] [Related]  

  • 15. EGFR-targeted immunoliposomes derived from the monoclonal antibody EMD72000 mediate specific and efficient drug delivery to a variety of colorectal cancer cells.
    Mamot C; Ritschard R; Küng W; Park JW; Herrmann R; Rochlitz CF
    J Drug Target; 2006 May; 14(4):215-23. PubMed ID: 16777680
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of the Dako EGFR pharmDx kit and Zymed EGFR antibody for assessment of EGFR status in colorectal adenocarcinoma.
    Buckley AF; Kakar S
    Appl Immunohistochem Mol Morphol; 2007 Sep; 15(3):305-9. PubMed ID: 17721276
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of EGFR, Her2 predict lymph node metastasis (LNM)-associated metastasis in colorectal cancer.
    Lu Y; Jingyan G; Baorong S; Peng J; Xu Y; Cai S
    Cancer Biomark; 2012; 11(5):219-26. PubMed ID: 23220854
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combined application of anti-VEGF and anti-EGFR attenuates the growth and angiogenesis of colorectal cancer mainly through suppressing AKT and ERK signaling in mice model.
    Ding C; Li L; Yang T; Fan X; Wu G
    BMC Cancer; 2016 Oct; 16(1):791. PubMed ID: 27729020
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression of membranous epidermal growth factor receptor in colorectal adenocarcinoma and its correlation with clinicopathological features.
    Mohammadi G; Jamialahmadi K; Lary S; Ghaffarzadegan K
    Pak J Biol Sci; 2011 Mar; 14(5):357-62. PubMed ID: 21874828
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epidermal Growth Factor Receptor Expression of Colorectal Carcinoma in Nigerian Patients.
    Lawan AI; Ogunbiyi JO
    West Afr J Med; 2020; 37(2):100-105. PubMed ID: 32150626
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.